U.S. Pharmaceutical Company Teligent Opened a Development Lab in Estonia
U.S. pharmaceutical company Teligent opened a development lab in Tallinn. It is Teligent’s only unit outside the US. But the 1 million euros spent on the lab is just the beginning of the US company’s investment in Estonia, Äripäev writes.
Teligent is a company mainly focusing on producing generic drugs.After Teligent acquired Canadian pharmaceutical company Alveda Pharmaceuticals, it needed to start thinking how to create a really efective chain of supply.
Many companies producing the drugs for Teligent work in Switzerland, France and Germany. All those places are far from Canada. This means that Teligent needed a site in Europe for its lab, preferrably in a country with suitable law and tax environment.
Though other destinations were considered, including Switzerland and Ireland, the final choice was made for Estonia. In addition to the tax rate, one of the things that helped to choose, was the ease of administering a company in Estonia. The company is now run using Estonian e-Residency.
The lab situated at Tehnopol in Tallinn specialises in analytical chemistry, supporting the main lab in the U.S. The lab will have 12 employees hired from Estonia and provided with additional training at the main lab in the U.S.A.